In the evolving landscape of medical diagnostics, few metrics have garnered as much niche yet critical attention as the BACII Score. While the term might sound like a forgotten standardized test or a complex financial rating, in the medical field—specifically in hepatology and oncology—the BACII Score (often referred to clinically as the Bile Acid Cologne II Index) is a prognostic biomarker used to predict patient outcomes.
First validated in a landmark 2018 study by the European Liver & Intestine Research Association (ELIRA), the BACII Score measures the interaction between serum bile acid profiles and secondary gut metabolites to determine the severity of cholestatic liver disease and the risk of hepatocellular carcinoma (HCC).
For patients diagnosed with Primary Sclerosing Cholangitis (PSC) or Primary Biliary Cholangitis (PBC), understanding your BACII Score is often the difference between waiting for a transplant and proactive intervention. bacii score
Ongoing research at the University of Cologne (the namesake of the index) is developing a Point-of-Care BACII strip—similar to a glucose test—that patients could use at home. Furthermore, AI models are now using single BACII measurements to predict the exact month of hepatic decompensation with 89% accuracy.
The BACII score is a numerical value derived from a 6-item questionnaire. It was developed by researchers to address a significant gap in addiction science: the need for a brief but sensitive tool that measures intensity rather than just extent (how much) of smoking. In the evolving landscape of medical diagnostics, few
Key Distinctions:
The BACII score typically ranges from 0 to 24. A higher score indicates a more severe, intense addiction to cigarettes. The BACII score typically ranges from 0 to 24
Just as a Zip Code ensures your mail reaches the right house, a BIC ensures your money reaches the right bank. It serves three critical functions: